Letter to the Editor: Comment on Implications of Ozempic and Other Semaglutide Medications for Facial Plastic Surgeons

Facial Plast Surg. 2023 Dec;39(6):e2-e3. doi: 10.1055/s-0044-1785450. Epub 2024 Apr 11.

Authors

Marco Bo Hansen¹, Katrine Louise Krogh Pedersen², Ting Jia³

Affiliations

¹ Global Medical Director, Novo Nordisk A/S, Søborg, Denmark.
² Safety Surveillance Specialist, Novo Nordisk A/S, Søborg, Denmark.
³ Senior Director, Medical and Science, Novo Nordisk A/S, Søborg, Denmark.

PMID: 38604245
DOI: 10.1055/s-0044-1785450

No abstract available

Publication types

Letter

MeSH terms

Face
Glucagon-Like Peptides / therapeutic use
Humans
Surgeons*
Surgery, Plastic*

Substances

semaglutide
Glucagon-Like Peptides